Related Experiment Video
Updated: May 25, 2026

Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
Henoch schonlein purpura--a 5-year review and proposed pathway
Louise Watson1, Amanda R W Richardson, Richard C L Holt
1Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Alder Hey Children's NHS Foundation Trust Hospital, Liverpool, United Kingdom. Louise.watson@liv.ac.uk
Insights
We developed a new nurse-led pathway to monitor Henoch Schonlein Purpura (HSP) in children. This pathway identifies children at high risk for kidney problems, improving early detection and management of HSP nephritis.
Area of Science:
- Pediatric Nephrology
- Rheumatology
- Clinical Pathway Development
Background:
- Henoch Schonlein Purpura (HSP) is the most common childhood vasculitis, often affecting the kidneys.
- Current monitoring pathways for HSP nephritis require critical assessment and revision.
- Standardized monitoring is crucial for understanding disease course and facilitating research.
Purpose of the Study:
- To clinically assess and revise a nurse-led monitoring pathway for Henoch Schonlein Purpura (HSP) in children.
- To determine the incidence and natural disease course of HSP nephritis.
- To develop an evidence-based pathway for screening poor renal outcomes in HSP.
Main Methods:
- A cohort of 102 children with HSP was monitored over five years using a nurse-led pathway.
- Incidence, disease course, and risk factors for renal involvement were analyzed.
- A revised pathway, The Alder Hey Henoch Schonlein Purpura Pathway, was developed based on data and literature.
Main Results:
- HSP incidence was 6.21 cases per 100,000 children/year.
- 46% had initial renal inflammation, 9% required renal referral, and 1% needed biopsy/immunosuppression.
- Older age and abnormal Day 7 urinalysis were associated with higher risk of renal referral; normal Day 7 urinalysis had 97% negative predictive value for normal renal outcome.
Conclusions:
- The revised Alder Hey Henoch Schonlein Purpura Pathway prioritizes monitoring based on Day 7 urine findings, focusing on high-risk patients.
- This standardized pathway can be adapted for various settings to improve HSP nephritis screening.
- Implementing standardized pathways will aid disease registries and future clinical trials for HSP.
Abstract:
Henoch Schonlein Purpura (HSP) is the commonest systemic vasculitis of childhood typically presenting with a palpable purpuric rash and frequently involving the renal system. We are the first group to clinically assess, critically analyse and subsequently revise a nurse led monitoring pathway for this condition.A cohort of 102 children presenting with HSP to a secondary/tertiary level UK paediatric hospital over a five year period, were monitored using a nurse led care pathway. Using this cohort, the incidence (6.21 cases per 100,000 children per year) and natural disease course of HSP nephritis (46% initial renal inflammation; 9% subsequent renal referral; 1% renal biopsy and immunosuppression) was determined. Older patients were at higher risk of requiring a renal referral (renal referral 12.3 (8.4-13.5) years vs. normal outcome 6.0 (3.7-8.5) years; p<0.01). A normal urinalysis on day 7 had a 97% (confidence interval 90 to 99%) negative predictive value in predicting a normal renal outcome.Using this data and existing literature base, The Alder Hey Henoch Schonlein Purpura Pathway was developed, a revised pathway for the screening of poor renal outcome in HSP. This is based on a six-month monitoring period for all patients presenting with HSP, which importantly prioritises patients according to the urine findings on day 7 and thus intensively monitors those at higher risk of developing nephritis. The pathway could be easily adapted for use in different settings and resources.The introduction of a standardised pathway for the monitoring of HSP will facilitate the implementation of disease registries to further our understanding of the condition and permit future clinical trials.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Peptic Ulcer Disease II: Pathophysiology
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Peptic Ulcer Disease II: Pathophysiology
Nephrotic Syndrome I : Introduction
Endocarditis II: Clinical Features of Infective Endocarditis
Nephrotic Syndrome II : Assessment and Medical Management

